Source - SMW
Sareum Holdings welcomed news that Sierra Oncology had reported positive preliminary clinical data from two in-human studies.

Sierra Oncology is the licence holder for Chk1 inhibitor SRA737.

It reported the data from its two first-in-human Phase 1/2 studies of SRA737 as monotherapy and as SRA737+LDG at the 2019 Annual Meeting of the American Society of Clinical Oncology in Chicago.

Anti-cancer activity was demonstrated across multiple indications and genetic contexts, with SRA737+LDG specifically achieving a notable 30% response rate in anogenital cancer patients.

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.